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Abstract Two clinical trials, the Randomized ALdosterone
Evaluation Study (RALES) and the EPlerenone HEart
failure and SUrvival Study (EPHESUS), have recently
shown that mineralocorticoid receptor (MR) antagonists
reduce mortality in patients with heart failure on top of
ACE inhibition. This effect could not be attributed solely to
blockade of the renal MR-mediated effects on blood
pressure, and it has therefore been proposed that aldoste-
rone, the endogenous MR agonist, also acts extrarenally, in
particular in the heart. Indeed, MR are present in cardiac
tissue, and possibly aldosterone synthesis occurs in the
heart. This review critically addresses the following ques-
tions: (1) is aldosterone synthesized at cardiac tissue sites,
(2) what agonist stimulates cardiac MR normally, and (3)
what effects are mediated by aldosterone/MR in the heart
that could explain the beneficial effects of MR blockade in
heart failure? Conclusions are that most, if not all, of
cardiac aldosterone originates in the circulation (i.e., is of
adrenal origin), and that glucocorticoids, in addition to
aldosterone, may serve as the endogenous agonist of
cardiac MR. MR-mediated effects in the heart include
effects on endothelial function, cardiac fibrosis and hyper-
trophy, oxidative stress, cardiac inotropy, coronary flow,
and arrhythmias. Some of these effects occur via or in
synergy with angiotensin II, and involve a non-MR-
mediated mechanism. This raises the possibility that
aldosterone synthase inhibitors might exert beneficial
effects on top of MR blockade.
Keywords Aldosterone.Mineralocorticoidreceptor.
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Introduction
The renin-angiotensin-aldosterone system (RAAS) has been
viewed conventionally as a circulating system, involved in
the regulation of salt, fluid homeostasis and blood pressure.
Kidney-derived renin cleaves liver-derived angiotensinogen
to form angiotensin (Ang) I in circulating blood (Fig. 1).
Angiotensin-converting enzyme (ACE), located at the
luminal side of the endothelium, subsequently converts
Ang I to Ang II. Ang II exerts its effects via stimulation of
Ang II type 1 (AT1) and type 2 (AT2) receptors. Besides
acting as a vasoconstrictor via AT1 receptors, Ang II also
stimulates the formation of the sodium-retaining hormone
aldosterone. Aldosterone mediates its cellular effects by
binding to the mineralocorticoid receptor (MR), a member
of the steroid/thyroid/retinoid/orphan receptor family of
transcription factors.
This classic concept has been updated in the past two
decades. It is now believed that some or all of the
components of the RAAS are synthesized locally in tissues
such as the heart and vessel wall (Danser 2003; Tom et al.
2003). For instance, in the heart, Ang II is synthesized
locally by cardiac ACE following uptake of renin and
angiotensinogen from the circulation (Danser et al. 1994;
van Kats et al. 1998). This Ang II subsequently stimulates
cardiac AT1 and AT2 receptors (Batenburg et al. 2004; van
Kats et al. 2000). Local synthesis of Ang II at cardiac tissue
sites is in agreement with the observation that the beneficial
effects of ACE inhibitors in heart failure are, at least in part,
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Traditionally, treatment of heart failure and hypertension
has been performed mainly on the basis of the renin-
angiotensin system (RAS) rather than the RAAS, with the
assumption that aldosterone will be suppressed once Ang II
formation is blocked. However, aldosterone formation does
not stay suppressed during prolonged RAS blocking
therapy. After 3 months of therapy, aldosterone levels start
to rise again and they continue to do so due to “Ang II
reactivation” or “aldosterone escape” (Farquharson and
Struthers 2002; Jorde et al. 2002).
Two clinical trials, the Randomized ALdosterone Eval-
uation Study (RALES) (Pitt et al. 1999) and the EPlerenone
HEart failure and SUrvival Study (EPHESUS) (Pitt et al.
2003), have convincingly indicated that MR antagonists
reduce mortality in patients with heart failure and systolic
left ventricular dysfunction post-myocardial infarction on
top of ACE inhibition. In particular, a reduction in the rate
of sudden death was observed. These results draw attention
to the importance of aldosterone as an independent risk
factor in the pathophysiology of cardiovascular disease.
The benefit of MR antagonists during RAS blockade is not
yet fully understood. Their effects cannot be attributed
solely to blockade of the renal MR-mediated effects on
blood pressure (Pitt et al. 1999, 2003), and it is now
generally assumed that aldosterone also acts extrarenally, in
agreement with the concept of local RAAS.
Indeed, MR have been demonstrated in the heart, both at
the mRNA and protein level (Lombès et al. 1995).
Importantly, the enzymes required for the synthesis of
aldosterone appear to be expressed in the human heart as
well (Young et al. 2001). Together with the fact that Ang II
is capable of increasing the aldosterone levels in isolated rat
hearts and blood vessels (Silvestre et al. 1998; Takeda et al.
1997), these data suggest that aldosterone, like Ang II, may
be formed and act locally in the heart. This review
addresses the following questions: (1) is aldosterone really
synthesized at cardiac tissue sites, (2) what agonist
stimulates cardiac MR, and (3) what effects are mediated
by aldosterone/MR in the heart that could explain the
beneficial effects of MR blockade in heart failure?
Aldosterone synthesis at cardiac tissue sites?
Aldosterone, a steroid that was originally discovered in
1953, is secreted by the zona glomerulosa cells of the
adrenal cortex. The kidney is the major target for adrenal
aldosterone to increase sodium (and consequently water)
reabsorption and potassium excretion. The production of
aldosterone is regulated at two critical enzyme steps: (1) the
formation of pregnenolone from cholesterol by the mito-
chondrial enzyme P450scc (side-chain cleavage), and (2)
the conversion of corticosterone to aldosterone by cyto-
chrome P450 11β-hydroxylase 2 (CYP11B2, ‘aldosterone
synthase’). Aldosterone synthesis in the adrenal cortex is
regulated by Ang II, potassium and, more weakly, sodium
and adrenocorticotrophic hormone.
Extra-adrenal aldosterone synthesis has been proposed in
heart (Silvestre et al. 1998), brain (Gomez-Sanchez et al.
1997) and vessel wall (Takeda et al. 1995, 1997). The rat
heart expresses the steroidogenic acute regulatory (StAR)
protein and aldosterone synthase, although at 100-fold lower
levels than the adrenal (Casal et al. 2003; Silvestre et al.
1998). The StAR protein facilitates intramitochondrial
cholesterol transfer, the rate-limiting step of steroidogenesis.
Aldosterone synthase expression has also been proposed in
the human heart (Tsybouleva et al. 2004; Young et al. 2001).
In support of the functional importance of such expression,
net release of aldosterone was observed across the human
coronary vascular bed (Nakamura et al. 2004). However,
other studies demonstrated the opposite (i.e., cardiac
aldosterone extraction) (Hayashi et al. 2003), whereas it
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Fig. 1 The renin-angiotensin-aldosterone system. Angiotensin II
activates angiotensin II type 1 and type 2 (AT1 and AT2) receptors.
AT1 receptor activation in the adrenal results in the synthesis and
release of aldosterone, which subsequently exerts ‘genomic’ (after
hours, involving protein synthesis) or ‘non-genomic’ (within minutes,
not involving protein synthesis) effects through either mineralocorti-
coid receptors (MR) or other, as yet unidentified, receptors. MR may
occur both intracellular and on the cell membrane. Aldosterone
upregulates both AT1 and AT2 receptors, and AT1 receptor activation
also results in MR stimulation in an aldosterone-independent manner
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correlated closely with the cardiac levels of renin. Since
the latter is exclusively of renal origin (i.e., blood-derived)
(Danser et al. 1994, 1997; Saris et al. 2001), its correlation
with aldosterone argues against independent aldosterone
synthesis at cardiac tissue sites. Furthermore, recent careful
studies in rats, paying great attention to the measurement of
aldosterone in cardiac tissue, did not confirm the idea of
local synthesis of aldosterone in the rat heart (Fiebeler et al.
2005; Gomez-Sanchez et al. 2004). In these studies, the
cardiac aldosterone levels were much lower than previously
reported by others (Silvestre et al. 1998). Furthermore, the
cardiac levels correlated closely with the plasma levels of
aldosterone, and they decreased to levels at or below the
detection limit after adrenalectomy.
Subsequent perfusion studies with aldosterone in the
isolated Langendorff heart (Chai et al. 2006) showed that
the steroid rapidly accumulated in cardiac tissue, not only
in extracellular (interstitial) fluid but also in a second, as yet
unidentified, compartment. At steady state, the aldosterone
tissue levels (expressed per g wet weight) were higher than
its levels in coronary effluent (expressed per ml). Washout
from the second compartment occurred relatively rapid
(half life<10 min), suggesting that it represented cell
surface-bound rather than internalized aldosterone (Fig. 2).
This pattern resembles that of cardiac renin, which also
accumulates in extracellular fluid and binds to membrane
receptors (Danser et al. 1994; de Lannoy et al. 1997; Saris
et al. 2001). After prolonged washout, cardiac aldosterone
became undetectable. Thus, on the one hand, the heart
displays a large capacity to accumulate aldosterone. This
explains why the levels of cardiac aldosterone in rats can be
up to 10-fold higher than in serum (Fiebeler et al. 2005).
On the other hand, cardiac aldosterone disappears rapidly
during perfusion with aldosterone-free buffer. This provides
an explanation for the ‘release’ of aldosterone across the
coronary vascular bed in humans and rats (Takeda et al.
2000). The majority of cardiac aldosterone, if not all, is
however derived from the circulation, i.e., is not synthesized
locally, both under normal and pathological conditions
(Chai et al. 2006; Fiebeler et al. 2005; Gomez-Sanchez
et al. 2004).
Activation of cardiac mineralocorticoid receptors
by aldosterone?
MRs occur both in Na
+-transporting epithelia (e.g., kidney,
colon) and non-epithelial tissues such as brain (de Kloet
et al. 2000), heart (cardiomyocytes) (Lombès et al. 1995),
and blood vessels (endothelial and smooth muscle cells)
(Lombès et al. 1992; Oberleithner 2005; Oberleithner et al.
2004). The presence of MR in the cardiovascular system
has been confirmed both at the mRNA and protein level in
animals as well as in humans (Lombès et al. 1992).
MRs bind mineralocorticoids and glucocorticoids with
equal affinity (Kd≈0.5–2 nM) (Arriza et al. 1987; Lombès
et al. 1994). Yet, the circulating concentrations of gluco-
corticoids are several orders of magnitude higher than those
of aldosterone (Fig. 3). Selectivity of aldosterone binding to
MR is achieved by co-expression of 11β-hydroxysteroid
dehydrogenase type 2 (11βHSD2) (Alzamora et al. 2000).
This enzyme converts cortisol (the endogenous glucocorti-
coid in humans) and corticosterone (the endogenous
glucocorticoid in rats) to their non-MR-binding metabolites
cortisone and 11-dehydrocorticosterone (Fig. 3). In addi-
tion, the off-rate of aldosterone from the MR is five times
lower than that of glucocorticoids (Lombès et al. 1994), and
thus it is possible that MR also discriminate aldosterone
from glucocorticoids, at least in part, independently of
11βHSD2.
In the kidney, 11βHSD2 expression is high enough to
allow selective MR stimulation by aldosterone. In contrast,
in the heart, the 11βHSD2 levels are almost negligible
(Nagata et al. 2006), and it has therefore been proposed that
cardiac MR are occupied by cortisol/corticosterone rather
than aldosterone (Funder 2005b; Gomez-Sanchez et al.
2004;N a g a t ae ta l .2006). In fact, the endogenous
glucocorticoid levels are high enough to keep all cardiac
MR permanently occupied (Funder 2005b). Such perma-
nent occupation does not apply to glucocorticoid receptors,
since they have a ≈30-fold lower affinity for cortisol/
corticosterone than MR (Fig. 3). Glucocorticoids are
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Fig. 2 Washout of aldosterone from the isolated perfused rat
Langendorff heart after its exposure to 10 nmol/l aldosterone for
30 min. Data are modified from Chai et al. (2006)
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effect following binding to MR) in kidney (Good et al.
2002) and heart (Qin et al. 2003), whereas in the vessel
wall, during 11βHSD2 blockade with carbenoxolone, they
act as agonists (Alzamora et al. 2000). The latter could
relate to the observation that glucocorticoid-MR complexes
become activated as a result of the generation of reactive
oxygen species (ROS). Under such circumstances, MR
antagonists may exert effects by blocking the consequences
of glucocorticoid-MR complex activation rather than
aldosterone-MR activation (Funder 2005b; Nagata et al.
2006). The increased expression in the failing rat heart of
the enzyme 11β-hydroxysteroid dehydrogenase type 1
(11βHSD1), which reactivates 11-dehydrocorticosterone
to corticosterone, further supports this concept (Nagata
et al. 2006).
Genomic versus non-genomic effects
The classical MR-mediated effects of aldosterone are
referred to as ‘genomic’ effects. These effects involve
binding of aldosterone to intracellular MRs, and the
translocation of the steroid-MR complex to the nucleus,
where it acts as a transcriptional regulator, inducing protein
synthesis (in particular synthesis of the epithelial Na
+
channel) after several hours. Genomic effects can be
inhibited by agents that block either transcription
(e.g., actinomycin D) or translation (e.g., cycloheximide).
In addition to its genomic effects, which occur after
hours, aldosterone also exerts rapid effects (within minutes)
in various tissues, e.g., heart and vasculature. These effects
are usually described as ‘non-genomic’, since they do not
involve DNA-directed, RNA-mediated protein synthesis.
For instance, aldosterone rapidly affects cardiac inotropy
and facilitates both vasodilation and vasoconstriction
(Barbato et al. 2002; Liu et al. 2003; Mazak et al. 2004;
Michea et al. 2005; Mihailidou et al. 2004; Schmidt et al.
2003). In many (but not all) cases, these effects could not
be blocked by the MR antagonist spironolactone, and
therefore the existence of a novel (membrane-associated?)
aldosterone receptor has been proposed (Funder 2005a;
Wehling et al. 1995). However, despite numerous efforts in
the past decade, no convincing data toward the character-
ization of a membrane receptor for aldosterone have been
put forward (Funder 2005a; Wehling 2005). Consequently,
it is not unlikely that these effects are after all also being
mediated via the classical (intracellular) MR (Funder
2005a). If so, an explanation must be provided for the lack
of effect of spironolactone toward the rapid aldosterone-
induced actions in vitro. Possibly, via modification or
dimerization, classical MR can attain an atypical pharma-
cology, thereby no longer allowing the binding of MR
antagonists such as spironolactone. In addition, spironolac-
tone exerts MR-independent effects of its own, i.e., it
blocks human Ether-a-Go-Go-Related gene K
+ channels
(Caballero et al. 2003) and inhibits calcium entry (Cargnelli
et al. 2001). Thus, to solve this issue, future studies should
plasma levels (nM) aldosterone 0.1 – 1
glucocorticoid hormones 10 – 1000
affinity constant (nM) GR 0.5 – 2
MR 10 –20
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Eplerenone displays increased selectivity for the MR over
other steroid receptors, although its affinity for the MR in
vitro is 10- to 20-fold lower than that of spironolactone.
The rapid, non-genomic actions involve activation of the
phospholipase C-protein kinase C (PKC)-inositol 1,4,5-
trisphosphate (IP3)-1,2 diacylglycerol (DAG) pathway,
which leads to an increase in intracellular Ca
2+ and
stimulation of the Na
+/H
+ exchanger (Barbato et al.
2004b; Funder 2005a; Liu et al. 2003; Lösel et al. 2002;
Mihailidou et al. 2004; Sato et al. 1997). The latter causes a
rise in intracellular Na
+, which subsequently activates
Na
+/K
+-ATPase. Interestingly, however, when the increase
in intracellular Na
+ is prevented, aldosterone decreases
Na
+/K
+-ATPase activity in a PKC-dependent manner
(Mihailidou et al. 2004). Thus, aldosterone may exert both
positive and negative inotropic effects. Other second
messenger pathways that have been linked to the rapid
effects of aldosterone include mitogen-activated protein
(MAP) kinases, ROS and the epidermal growth factor
receptor (Jaffe and Mendelsohn 2005; Mazak et al. 2004).
Effects of aldosterone in the cardiovascular system
Substantial evidence has emerged showing that aldosterone
induces adverse effects in the cardiovascular system. The
co-expression of 11βHSD2 and MR in human heart and
blood vessels (Glorioso et al. 2005; Jaffe and Mendelsohn
2005; Lombès et al. 1995), albeit at low levels, supports the
concept that these organs possess the cellular machinery
required for direct aldosterone action, irrespective of the
source of aldosterone.
Endothelial dysfunction
Aldosterone increases the volume and stiffness of endothe-
lial cells and induces gap formation, allowing irregular
diffusion pathways for large particles (Oberleithner 2005;
Oberleithner et al. 2004). This mechanism could contribute
to endothelial dysfunction observed in hyperaldosteronism.
The normalization of endothelial function by spironolac-
tone in patients with heart failure supports this concept
(Abiose et al. 2004; Macdonald et al. 2004).
Oxidative stress, inflammation, fibrosis and atherosclerosis
A growing number of studies support a specific role of the
MR as a mediator of oxidative stress and subsequent
inflammation, fibrosis and atherosclerosis. Elevations in
circulating aldosterone are accompanied by a pro-inflamma-
tory/fibrogenic vascular phenotype (Ahokas et al. 2005;B l a s i
et al. 2003; Sun et al. 2002), and since this phenomenon can
be blocked by both spironolactone and anti-oxidants (Sun et
al. 2002), it appears that aldosterone, via MR, induces
oxidative stress. Indeed, aldosterone upregulates various
subunits of NADPH oxidase and induces ROS generation
in mononuclear and vascular smooth muscle cells (Ahokas et
al. 2005;C a l oe ta l .2004; Mazak et al. 2004; Sun et al.
2002). In addition, aldosterone stimulates collagen synthesis
in cardiac fibroblasts (Brilla et al. 1994). Consequently,
aldosterone-induced cardiac fibrosis may be due to both
direct effects in the heart (mediated via fibroblasts) and
indirect peripheral effects (mediated via oxidative stress-
activated mononuclear cells) (Ahokas et al. 2005). The MR
antagonist eplerenone inhibited atherosclerosis both in
monkeys (Takai et al. 2005) and apolipoprotein-E deficient
mice (Suzuki et al. 2006) fed a high-cholesterol diet, most
likely by attenuating oxidative stress and inflammation.
Cardiac inotropy and coronary flow
In the isolated perfused rat Langendorff heart, aldosterone,
like Ang II, rapidly increased left ventricular pressure and
decreased coronary flow (Chai et al. 2005a;M o r e a ue ta l .
1996). Barbato et al. (2002) observed an increase in
cardiac contractility in combination with an increase in
coronary flow, but this may relate to the fact that the much
larger positive inotropic effects in their study had favoured
coronary vasodilation. Spironolactone and eplerenone did
not block the inotropic and vasoconstrictor/dilator effects
of aldosterone in the rat heart (Barbato et al. 2002;C h a i
et al. 2005a). In fact, spironolactone exerted similar
inotropic effects on top of aldosterone (Barbato et al.
2002;C h a ie ta l .2005a), and thus it appears that the
effects of aldosterone on inotropy and flow occur in a non-
MR-mediated manner.
In human myocardial trabeculae, aldosterone induced a
negative inotropic response (Fig. 4), in contrast to the well-
known positive inotropic effects of Ang II in this preparation
(Chai et al. 2005b). The PKC inhibitor chelerythrine
chloride, but not spironolactone or eplerenone, blocked this
negative inotropic effect, suggesting that it is mediated via a
non-MR in a PKC-dependent manner. The aldosterone
concentrations required to induce this effect were in the
high nanomolar range, i.e. a range that occurred in failing
hearts only (Chai et al. 2005b). Hydrocortisone, but not 17β-
estradiol, mimicked the effects of aldosterone, although at
lower potency (Fig. 4). The contrast between the effects of
aldosterone in the rat heart (positive inotropy) and the human
heart (negative inotropy) may relate to species differences.
However, there are alternative explanations. First, inotropic
effects in isolated trabeculae do not necessarily parallel
inotropic effects in intact hearts, since the latter also reflect
responses on coronary flow (Barbato et al. 2002). Second,
similar diametrically differing effects of aldosterone have
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different cells, or because different second messengers are
activated depending on the experimental circumstances
(Barbato et al. 2004b;C h a ie ta l .2005a;M i h a i l i d o ue ta l .
2004; Schmidt et al. 2003). Finally, the consequences of
PKC-induced regulation of Na
+-K
+ pump activity are tissue-
specific, and range from stimulation to inhibition, as
described above (Mihailidou et al. 2004; Therien and
Blostein 2000).
In human coronary arteries, aldosterone exerted no
constrictor or dilator effect by itself. However, prior
exposure to 1 μmol/L aldosterone greatly enhanced the
constrictor response to Ang II (Chai et al. 2005b). At the
second messenger level, this was reflected by an increase
in the level of phosphorylated p42/p44 MAP kinase.
Hydrocortisone and 17β-estradiol induced similar poten-
tiating effects, but only in the case of aldosterone did these
effects occur at the subnanomolar level, i.e., in a
physiological range. Future investigations should now
address to what degree this potentiation concerns aldoste-
rone-induced endothelial dysfunction (Oberleithner 2005;
Oberleithner et al. 2004), and/or an interaction with Ang II
at the level of smooth muscle cells, involving some or all
of the mediators that have recently been coupled to
aldosterone, e.g., the PKC-IP3-DAG pathway, Na
+/H
+
exchange, Na
+/K
+-ATPase, p38 MAP kinase, ROS and/
or the epidermal growth factor receptor (Jaffe and
Mendelsohn 2005; Liu et al. 2003; Mazak et al. 2004).
Finally, the possibility of aldosterone-induced, endotheli-
um-dependent, NO-mediated vasodilation, as proposed by
several investigators (Liu et al. 2003; Schmidt et al. 2003),
needs to be addressed.
Arrhythmias
MR blockade, in addition to standard therapy, reduced
sudden death in RALES and EPHESUS (Pitt et al. 1999,
2003). The mechanism responsible for this favorable effect
may rely on both renal changes in electrolyte excretion and
myocardial fibrosis inhibition. In addition, conditional MR
overexpression in the mouse heart, in the absence of
aldosteronemia, has been reported to result in severe
ventricular arrhythmias (Ouvrard-Pascaud et al. 2005).
Apparently, cardiac MR trigger arrhythmias directly, thus
providing an additional mechanism through which MR
antagonists reduce sudden death in patients. In support of
this possibility, spironolactone improved electrophysiolog-
ical parameters such as QT interval dispersion (Yee et al.
2001), and, in combination with the ACE inhibitor
fosinopril, reduced the arrhythmic score post-myocardial
infarction (Beck et al. 2001).
Furthermore, both spironolactone and eplerenone im-
proved the condition of the isolated perfused rat
Langendorff heart following ischemia and reperfusion,
as evidenced by a decrease in infarct size, a decrease in
arrhythmia incidence, and an increase in left ventricular
pressure recovery (Chai et al. 2005a, 2006) (Fig. 5).
Given the virtual lack of aldosterone in the isolated
perfused rat heart, it is unlikely that these effects are due
to blockade of endogenous aldosterone. In fact, concomi-
tant exposure to 100 nmol/l aldosterone did not further
deteriorate the condition of the heart during ischaemia and
reperfusion (Chai et al. 2006). A more likely explanation of
these findings is therefore that spironolactone and epler-
enone had blocked MR activation by endogenous gluco-
corticoids. Given the 1,000-fold higher levels of
corticosterone in the rat heart (Gomez-Sanchez et al.
2004), and assuming that the washout of glucocorticoids
resembles that of aldosterone, it can be calculated that, at
the time of ischaemia, sufficient glucocorticoid levels are
indeed present to allow cardiac MR activation. Such
activation might occur particularly under conditions which
facilitate ROS generation, such as ischaemia and reperfu-
sion (Funder 2005b; Nagata et al. 2006). Interestingly in
this regard, epidemiological observations have recently
shown that high-dose corticosteroids increase the risk of
developing atrial fibrillation (van der Hooft et al. 2006).
The cardioprotective effect of MR antagonism in the
Fig. 4 Inotropic effects of al-
dosterone, hydrocortisone and
17β-estradiol in human atrial
trabeculae. Left panel original
tracing from an experiment with
aldosterone (numbers represent -
log[aldosterone] in mol/L).
Right panel % change from
baseline contractile force. Data
have been obtained from Chai
et al. (2005b)
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be explained on the basis of the vasoconstrictor effect of
aldosterone, as proposed by Fujita et al. (2005), since
neither spironolactone nor eplerenone are capable of
blocking aldosterone-induced vasoconstriction in vitro
(Chai et al. 2005a, 2006).
Cardiac hypertrophy
Serum aldosterone levels associate with the variability of left
ventricular mass (LVM) in both healthy controls and subjects
with hypertension (Schunkert et al. 1997). The CYP11B2 C-
344T polymorphism associates with circulating aldosterone
levels, subjects with the T allele having higher aldosterone
levels than those with the CC genotype (Barbato et al.
2004a; Brand et al. 1998; Hautanena et al. 1998; Schunkert
et al. 1999;S t e l l ae ta l .2004). Given the association between
circulating aldosterone and LVM, it is not surprising that the
T allele also associates with LVM, both in subjects with
hypertension (Stella et al. 2004) and in patients with
hypertrophic cardiomyopathy (Chai et al. 2005c). Interest-
ingly, urinary 11β-HSD2 activity correlated directly with
LVM in essential hypertension (Glorioso et al. 2005). This
suggests that glucocorticoids also take part in the regulation
of LVM. Furthermore, two independent investigations have
shown that the CYP11B2 C-344T polymorphism is in strong
linkage disequilibrium with polymorphisms of the nearby
CYP11B1 gene (Ganapathipillai et al. 2005; Keavney et al.
2005). Since CYP11B1 (11β-hydroxylase) is the enzyme
catalyzing the final step in the biosynthesis of cortisol, the
association with the C-344T polymorphism might not only
relate to increased aldosterone levels, but also to reduced
11β-hydroxylase activity (Hilgers and Schmidt 2005).
Future studies, involving aldosterone, 11-deoxycortisol and
cortisol measurements in serum and/or urine (White and
Rainey 2005), should address this possibility.
Interaction with angiotensin II
Ang II stimulates the synthesis and release of aldosterone
in the adrenal, and thus MR blockade and/or aldosterone
synthase inhibition will exert beneficial effects in Ang II-
dependent models (Fiebeler et al. 2005;V i r d i se ta l .2002).
Remarkably, however, aldosterone also appears to exert its
effects, at least in part, via Ang II (or its receptors), and
both agonists, when applied together, act synergistically
(Gonzalez et al. 2005; Mazak et al. 2004;X i a oe ta l .2004)
(Fig. 1). For instance, in cultured rat aortic smooth muscle
cells, nanomolar concentrations of aldosterone enhanced
the effect of Ang II on DNA synthesis (Chai et al. 2005a).
Unexpectedly, higher (micromolar) aldosterone concen-
trations reduced DNA synthesis, both in smooth muscle
cells and in cardiac myocytes. Such high aldosterone
concentrations also reduced collagen synthesis in cardiac
fibroblasts. These latter inhibitory effects most likely
reflect glucocorticoid receptor activation by aldosterone
(Arriza et al. 1987;S a t oa n dF u n d e r1996). Furthermore,
in human coronary artery smooth muscle cells, Ang II
stimulated MR-mediated gene expression in an aldoste-
rone-independent manner, suggesting direct MR activation
by post-translational modifications such as phosphoryla-
tion (Jaffe and Mendelsohn 2005).
Fig. 5 Infarct size (left panel),
recovery of left ventricular
pressure (LVP) (middle panel),
and incidence of arrhythmias
(right panel) in rat hearts that
were subjected to 45 min left
anterior descending coronary
artery occlusion, followed by
3 h of reperfusion, after either
no pretreatment (C, control)
or a 15-min exposure
to 100 nmol/l aldosterone (A),
1 μmol/l spironolactone (S),
1 μmol/l eplerenone (E)o r
100 nmol/l aldosterone+1 μmol/
L eplerenone (A+E). Data are
from Chai et al. (2005a, 2006).
*P<0.05 versus control
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cardioprotective?
The beneficial effects of MR antagonists in heart failure
cannot be explained on the basis of their renal and/or blood
pressure-lowering effects. Most likely they relate, at least in
part, to blockade of a wide range of MR-mediated effects
in the heart, including endothelial dysfunction, a decrease
in cardiac inotropy and coronary flow, and the induction of
fibrosis, hypertrophy, oxidative stress and arrhythmias.
Some of these effects occur via or in synergy with Ang II.
Given the virtual absence of aldosterone production in the
heart, and in view of the low cardiac levels of the cortisol-
inactivating enzyme 11β-HSD2, it is unlikely that, under all
conditions, aldosterone is the endogenous agonist of cardiac
MR. Thus, some of the MR-mediated effects in the heart
may be due to MR activation by glucocorticoids, particu-
larly when ROS levels are high. The aldosterone levels in
the failing human heart, but not those in the healthy heart,
are high enough to be of functional importance. Whether
some of the above (acute, ‘non-genomic’) in vitro effects of
aldosterone are mediated via a non-MR-mediated mecha-
nism remains to be proven, in particular because no
(membrane receptor) candidate has been identified so far
that induces these effects. If true, however, aldosterone
synthase inhibitors might be expected to exert beneficial
effects on top of MR blockade.
References
Abiose AK, Mansoor GA, Barry M, Soucier R, Nair CK, Hager D
(2004) Effect of spironolactone on endothelial function in
patients with congestive heart failure on conventional medical
therapy. Am J Cardiol 93:1564–1566
Ahokas RA, Sun Y, Bhattacharya SK, Gerling IC, Weber KT (2005)
Aldosteronism and a proinflammatory vascular phenotype: role
of Mg2+, Ca2+, and H2O2 in peripheral blood mononuclear
cells. Circulation 111:51–57
Alzamora R, Michea L, Marusic ET (2000) Role of 11beta-
hydroxysteroid dehydrogenase in nongenomic aldosterone effects
in human arteries. Hypertension 35:1099–1104
Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL,
Housman DE, Evans RM (1987) Cloning of human mineralo-
corticoid receptor complementary DNA: structural and functional
kinship with the glucocorticoid receptor. Science 237:268–275
Barbato A, Russo P, Siani A, Folkerd EJ, Miller MA, Venezia A,
Grimaldi C, Strazzullo P, Cappuccio FP (2004a) Aldosterone
synthase gene (CYP11B2) C-344T polymorphism, plasma
aldosterone, renin activity and blood pressure in a multi-ethnic
population. J Hypertens 22:1895–1901
Barbato JC, Mulrow PJ, Shapiro JI, Franco-Saenz R (2002) Rapid
effects of aldosterone and spironolactone in the isolated working
rat heart. Hypertension 40:130–135
Barbato JC, Rashid S, Mulrow PJ, Shapiro JI, Franco-Saenz R
(2004b) Mechanisms for aldosterone and spironolactone-induced
positive inotropic actions in the rat heart. Hypertension 44:751–
757
Batenburg WW, Garrelds IM, Bernasconi CC, Juillerat-Jeanneret L,
van Kats JP, Saxena PR, Danser AHJ (2004) Angiotensin II type
2 receptor-mediated vasodilation in human coronary micro-
arteries. Circulation 109:2296–2301
Beck L, Blanc-Guillemaud V, Cherif OK, Jover B, Davy JM (2001)
Effects of spironolactone and fosinopril on the spontaneous and
chronic ventricular arrhythmias in a rat model of myocardial
infarction. Cardiology 96:85–93
Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon
EG (2003) Aldosterone/salt induces renal inflammation and
fibrosis in hypertensive rats. Kidney Int 63:1791–1800
Brand E, Chatelain N, Mulatero P, Fery I, Curnow K, Jeunemaitre X,
Corvol P, Pascoe L, Soubrier F (1998) Structural analysis and
evaluation of the aldosterone synthase gene in hypertension.
Hypertension 32:198–204
Brilla CG, Zhou G, Matsubara L, Weber KT (1994) Collagen
metabolism in cultured adult rat cardiac fibroblasts: response to
angiotensin II and aldosterone. J Mol Cell Cardiol 26:809–820
Caballero R, Moreno I, Gonzalez T, Arias C, Valenzuela C, Delpon E,
Tamargo J (2003) Spironolactone and its main metabolite,
canrenoic acid, block human ether-a-go-go-related gene chan-
nels. Circulation 107:889–895
Calo LA, Zaghetto F, Pagnin E, Davis PA, De Mozzi P, Sartorato P,
Martire G, Fiore C, Armanini D (2004) Effect of aldosterone and
glycyrrhetinic acid on the protein expression of PAI-1 and p22
(phox) in human mononuclear leukocytes. J Clin Endocrinol
Metab 89:1973–1976
Cargnelli G, Trevisi L, Debetto P, Luciani S, Bova S (2001) Effects of
canrenone on aorta and right ventricle of the rat. J Cardiovasc
Pharmacol 37:540–547
Casal AJ, Silvestre JS, Delcayre C, Capponi AM (2003) Expression
and modulation of steroidogenic acute regulatory protein mes-
senger ribonucleic acid in rat cardiocytes and after myocardial
infarction. Endocrinology 144:1861–1868
Chai W, Garrelds IM, Arulmani U, Schoemaker RG, Lamers JMJ,
Danser AHJ (2005a) Genomic and non-genomic effects of
aldosterone in the rat heart: why is spironolactone cardioprotec-
tive? Br J Pharmacol 145:664–671
Chai W, Garrelds IM, de Vries R, Batenburg WW, van Kats JP, Danser
AHJ (2005b) Nongenomic effects of aldosterone in the human
heart. Interaction with Angiotensin II. Hypertension 46:701–706
Chai W, van Schaik RHN, van Fessem MA, Kofflard MJM, ten Cate
FJ, Danser AHJ (2005c) Aldosterone and cardiac hypertrophy in
subjects with hypertrophic cardiomyopathy. Circulation 112
(suppl II):356 (Abstract)
Chai W, Garrelds IM, de Vries R, Danser AHJ (2006) Cardiopro-
tective effects of eplerenone in the rat heart: interaction with
locally synthesized or blood-derived aldosterone? Hypertension
47:665–670
Danser AHJ (2003) Local renin-angiotensin systems: the unanswered
questions. Int J Biochem Cell Biol 35:759–768
Danser AHJ, van Kats JP, Admiraal PJJ, Derkx FHM, Lamers JMJ,
Verdouw PD, Saxena PR, Schalekamp MADH (1994) Cardiac
renin and angiotensins. Uptake from plasma versus in situ
synthesis. Hypertension 24:37–48
Danser AHJ, van Kesteren CAM, Bax WA, Tavenier M, Derkx FHM,
Saxena PR, Schalekamp MADH (1997) Prorenin, renin, angio-
tensinogen, and angiotensin-converting enzyme in normal and
failing human hearts. Evidence for renin binding. Circulation
96:220–226
de Kloet ER, van Acker SA, Sibug RM, Oitzl MS, Meijer OC,
Rahmouni K, de Jong W (2000) Brain mineralocorticoid
receptors and centrally regulated functions. Kidney Int
57:1329–1336
de Lannoy LM, Danser AHJ, van Kats JP, Schoemaker RG, Saxena
PR, Schalekamp MADH (1997) Renin-angiotensin system
160 Naunyn-Schmiedeberg’s Arch Pharmacol (2006) 374:153–162components in the interstitial fluid of the isolated perfused rat
heart. Local production of angiotensin I. Hypertension 29:1240–
1251
Farquharson CA, Struthers AD (2002) Gradual reactivation over time
of vascular tissue angiotensin I to angiotensin II conversion
during chronic lisinopril therapy in chronic heart failure. J Am
Coll Cardiol 39:767–775
Fiebeler A, Nussberger J, Shagdarsuren E, Rong S, Hilfenhaus G, Al-
Saadi N, Dechend R, Wellner M, Meiners S, Maser-Gluth C,
Jeng AY, Webb RL, Luft FC, Müller DN (2005) Aldosterone
synthase inhibitor ameliorates angiotensin II-induced organ
damage. Circulation 111:3087–3094
Fujita M, Minamino T, Asanuma H, Sanada S, Hirata A, Wakeno M,
Myoishi M, Okuda H, Ogai A, Okada K, Tsukamoto O, Koyama
H, Hori M, Kitakaze M (2005) Aldosterone nongenomically
worsens ischemia via protein kinase C-dependent pathways in
hypoperfused canine hearts. Hypertension 46:113–117
Funder JW (2005a) The nongenomic actions of aldosterone. Endocr
Rev 26:313–321
Funder JW (2005b) RALES, EPHESUS and redox. J Steroid Biochem
Mol Biol 93:121–125
Ganapathipillai S, Laval G, Hoffmann IS, Castejon AM, Nicod J,
Dick B, Frey FJ, Frey BM, Cubeddu LX, Ferrari P (2005)
CYP11B2-CYP11B1 haplotypes associated with decreased 11
beta-hydroxylase activity. J Clin Endocrinol Metab 90:1220–
1225
Glorioso N, Filigheddu F, Parpaglia PP, Soro A, Troffa C, Argiolas G,
Mulatero P (2005) 11beta-Hydroxysteroid dehydrogenase type 2
activity is associated with left ventricular mass in essential
hypertension. Eur Heart J 26:498–504
Gomez-Sanchez CE, Zhou MY, Cozza EN, Morita H, Foecking MF,
Gomez-Sanchez EP (1997) Aldosterone biosynthesis in the rat
brain. Endocrinology 138:3369–3373
Gomez-Sanchez EP, Ahmad N, Romero DG, Gomez-Sanchez CE
(2004) Origin of aldosterone in the rat heart. Endocrinology
145:4796–4802
Gonzalez M, Lobos L, Castillo F, Galleguillos L, Lopez NC, Michea
L (2005) High-salt diet inhibits expression of angiotensin type 2
receptor in resistance arteries. Hypertension 45:853–859
Good DW, George T, Watts BA 3rd (2002) Aldosterone inhibits HCO
absorption via a nongenomic pathway in medullary thick
ascending limb. Am J Physiol Renal Physiol 283:F699–706
Hagendorf A, Koper JW, de Jong FH, Brinkmann AO, Lamberts SWJ,
Feelders RA (2005) Expression of the human glucocorticoid
receptor splice variants alpha, beta, and P in peripheral blood
mononuclear leukocytes in healthy controls and in patients with
hyper- and hypocortisolism. J Clin Endocrinol Metab 90:6237–
6243
Hautanena A, Lankinen L, Kupari M, Janne OA, Adlercreutz H,
Nikkila H, White PC (1998) Associations between aldosterone
synthase gene polymorphism and the adrenocortical function in
males. J Intern Med 244:11–18
Hayashi M, Tsutamoto T, Wada A, Tsutsui T, Ishii C, Ohno K, Fujii
M, Taniguchi A, Hamatani T, Nozato Y, Kataoka K, Morigami N,
Ohnishi M, Kinoshita M, Horie M (2003) Immediate adminis-
tration of mineralocorticoid receptor antagonist spironolactone
prevents post-infarct left ventricular remodeling associated with
suppression of a marker of myocardial collagen synthesis in
patients with first anterior acute myocardial infarction.
Circulation 107:2559–2565
Hilgers KF, Schmidt BM (2005) Gene variants of aldosterone
synthase and hypertension. J Hypertens 23:1957–1959
Jaffe IZ, Mendelsohn ME (2005) Angiotensin II and aldosterone
regulate gene transcription via functional mineralocortocoid
receptors in human coronary artery smooth muscle cells. Circ
Res 96:643–650
Jorde UP, Vittorio T, Katz SD, Colombo PC, Latif F, Le Jemtel TH
(2002) Elevated plasma aldosterone levels despite complete
inhibition of the vascular angiotensin-converting enzyme in
chronic heart failure. Circulation 106:1055–1057
Keavney B, Mayosi B, Gaukrodger N, Imrie H, Baker M, Fraser R,
Ingram M, Watkins H, Farrall M, Davies E, Connell J (2005)
Genetic variation at the locus encompassing 11-beta hydroxylase
and aldosterone synthase accounts for heritability in cortisol
precursor (11-deoxycortisol) urinary metabolite excretion. J Clin
Endocrinol Metab 90:1072–1077
Liu SL, Schmuck S, Chorazcyzewski JZ, Gros R, Feldman RD (2003)
Aldosterone regulates vascular reactivity: short-term effects
mediated by phosphatidylinositol 3-kinase-dependent nitric oxide
synthase activation. Circulation 108:2400–2406
Lombès M, Oblin ME, Gasc JM, Baulieu EE, Farman N, Bonvalet JP
(1992) Immunohistochemical and biochemical evidence for a
cardiovascular mineralocorticoid receptor. Circ Res 71:503–510
Lombès M, Kenouch S, Souque A, Farman N, Rafestin-Oblin ME
(1994) The mineralocorticoid receptor discriminates aldosterone
from glucocorticoids independently of the 11 beta-hydroxyste-
roid dehydrogenase. Endocrinology 135:834–840
Lombès M, Alfaidy N, Eugene E, Lessana A, Farman N, Bonvalet JP
(1995) Prerequisite for cardiac aldosterone action. Mineralocor-
ticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the
human heart. Circulation 92:175–182
Lösel R, Feuring M, Wehling M (2002) Non-genomic aldosterone
action: from the cell membrane to human physiology. J Steroid
Biochem Mol Biol 83:167–171
Macdonald JE, Kennedy N, Struthers AD (2004) Effects of spirono-
lactone on endothelial function, vascular angiotensin converting
enzyme activity, and other prognostic markers in patients with
mild heart failure already taking optimal treatment. Heart
90:765–770
Mazak I, Fiebeler A, Müller DN, Park JK, Shagdarsuren E, Lindschau
C, Dechend R, Viedt C, Pilz B, Haller H, Luft FC (2004)
Aldosterone potentiates angiotensin II-induced signaling in
vascular smooth muscle cells. Circulation 109:2792–2800
Michea L, Delpiano AM, Hitschfeld C, Lobos L, Lavandero S, Marusic
ET (2005) Eplerenone blocks nongenomic effects of aldosterone
on the Na+/H+ exchanger, intracellular Ca2+ levels, and
vasoconstriction in mesenteric resistance vessels. Endocrinology
146:973–980
Mihailidou AS, Mardini M, Funder JW (2004) Rapid, nongenomic
effects of aldosterone in the heart mediated by epsilon protein
kinase C. Endocrinology 145:773–780
MoreauD,ChardignyJM, RochetteL(1996) Effectsofaldosterone and
spironolactone on the isolated perfused rat heart. Pharmacology
53:28–36
Nagata K, Obata K, Xu J, Ichihara S, Noda A, Kimata H, Kato T,
Izawa H, Murohara T, Yokota M (2006) Mineralocorticoid
receptor antagonism attenuates cardiac hypertrophy and failure
in low-aldosterone hypertensive rats. Hypertension 47:656–664
Nakamura S, Yoshimura M, Nakayama M, Ito T, Mizuno Y, Harada E,
Sakamoto T, Saito Y, Nakao K, Yasue H, Ogawa H (2004)
Possible association of heart failure status with synthetic balance
between aldosterone and dehydroepiandrosterone in human heart.
Circulation 110:1787–1793
Oberleithner H (2005) Aldosterone makes human endothelium stiff
and vulnerable. Kidney Int 67:1680–1682
Oberleithner H, Ludwig T, Riethmuller C, Hillebrand U, Albermann
L, Schafer C, Shahin V, Schillers H (2004) Human endothelium:
target for aldosterone. Hypertension 43:952–956
Ouvrard-Pascaud A, Sainte-Marie Y, Benitah JP, Perrier R, Soukaseum
C, Cat AN, Royer A, Le Quang K, Charpentier F, Demolombe S,
Mechta-Grigoriou F, Beggah AT, Maison-Blanche P, Oblin ME,
Delcayre C, Fishman GI, Farman N, Escoubet B, Jaisser F (2005)
Naunyn-Schmiedeberg’s Arch Pharmacol (2006) 374:153–162 161Conditional mineralocorticoid receptor expression in the heart
leads to life-threatening arrhythmias. Circulation 111:3025–3033
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A,
Palensky J, Wittes J (1999) The effect of spironolactone on
morbidity and mortality in patients with severe heart failure.
Randomized Aldactone Evaluation Study Investigators. N Engl J
Med 341:709–717
Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman
R, Hurley S, Kleiman J, Gatlin M (2003) Eplerenone, a selective
aldosterone blocker, in patients with left ventricular dysfunction
after myocardial infarction. N Engl J Med 348:1309–1321
Qin W, Rudolph AE, Bond BR, Rocha R, Blomme EA, Goellner JJ,
Funder JW, McMahon EG (2003) Transgenic model of aldosterone-
driven cardiac hypertrophy and heart failure. Circ Res 93:69–76
Saris JJ, Derkx FHM, de Bruin RJA, Dekkers DHW, Lamers JMJ,
Saxena PR, Schalekamp MADH, Danser AHJ (2001) High-affinity
prorenin binding to cardiac man-6-P/IGF-II receptors precedes
proteolytic activation to renin. Am J Physiol 280:H1706–H1715
Sato A, Funder JW (1996) High glucose stimulates aldosterone-
induced hypertrophy via type I mineralocorticoid receptors in
neonatal rat cardiomyocytes. Endocrinology 137:4145–4153
Sato A, Liu JP, Funder JW (1997) Aldosterone rapidly represses
protein kinase C activity in neonatal rat cardiomyocytes in vitro.
Endocrinology 138:3410–3416
Schmidt BMW, Oehmer S, Delles C, Bratke R, Schneider MP,
Klingbeil A, Fleischmann EH, Schmieder RE (2003) Rapid
nongenomic effects of aldosterone on human forearm vascula-
ture. Hypertension 42:156–160
Schunkert H, Hense HW, Muscholl M, Luchner A, Kürzinger S,
Danser AHJ, Riegger GA (1997) Associations between circulat-
ing components of the renin-angiotensin-aldosterone system and
left ventricular mass. Heart 77:24–31
Schunkert H, Hengstenberg C, Holmer SR, Broeckel U, Luchner A,
Muscholl MW, Kurzinger S, Doring A, Hense HW, Riegger GA
(1999) Lack of association between a polymorphism of the
aldosterone synthase gene and left ventricular structure.
Circulation 99:2255–2260
Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C,
Moalic JM, Swynghedauw B, Delcayre C (1998) Myocardial
production of aldosterone and corticosterone in the rat. Physio-
logical regulation. J Biol Chem 273:4883–4891
Stella P, Bigatti G, Tizzoni L, Barlassina C, Lanzani C, Bianchi G,
Cusi D (2004) Association between aldosterone synthase
(CYP11B2) polymorphism and left ventricular mass in human
essential hypertension. J Am Coll Cardiol 43:265–270
Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT (2002)
Aldosterone-induced inflammation in the rat heart: role of
oxidative stress. Am J Pathol 161:1773–1781
Suzuki J, Iwai M, Mogi M, Oshita A, Yoshii T, Higaki J, Horiuchi M
(2006) Eplerenone with valsartan effectively reduces atheroscle-
rotic lesion by attenuation of oxidative stress and inflammation.
Arterioscler Thromb Vasc Biol 26:917–921
Takai S, Jin D, Muramatsu M, Kirimura K, Sakonjo H, Miyazaki M
(2005) Eplerenone inhibits atherosclerosis in nonhuman pri-
mates. Hypertension 46:1135–1139
Takeda Y, Miyamori I, Yoneda T, Iki K, Hatakeyama H, Blair IA,
Hsieh FY, Takeda R (1995) Production of aldosterone in isolated
rat blood vessels. Hypertension 25:170–173
Takeda Y, Miyamori I, Inaba S, Furukawa K, Hatakeyama H, Yoneda
T, Mabuchi H, Takeda R (1997) Vascular aldosterone in
genetically hypertensive rats. Hypertension 29:45–48
Takeda Y, Yoneda T, Demura M, Miyamori I, Mabuchi H (2000)
Cardiac aldosterone production in genetically hypertensive rats.
Hypertension 36:495–500
Therien AG, Blostein R (2000) Mechanisms of sodium pump
regulation. Am J Physiol Cell Physiol 279:C541–566
Tom B, Garrelds IM, Scalbert E, Stegmann APA, Boomsma F, Saxena
PR, Danser AHJ (2003) ACE- versus chymase-dependent
angiotensin II generation in human coronary arteries: a matter
of efficiency? Arterioscler Thromb Vasc Biol 23:251–256
Tsybouleva N, Zhang L, Chen S, Patel R, Lutucuta S, Nemoto S,
DeFreitas G, Entman M, Carabello BA, Roberts R, Marian AJ
(2004) Aldosterone, through novel signaling proteins, is a
fundamental molecular bridge between the genetic defect and
the cardiac phenotype of hypertrophic cardiomyopathy. Circula-
tion 109:1284–1291
van der Hooft CS, Sturkenboom MC, van Grootheest K, Kingma HJ,
Stricker BH (2006) Adverse drug reaction-related hospitalisations:
a nationwide study in The Netherlands. Drug Saf 29:161–168
van Kats JP, Danser AHJ, van Meegen JR, Sassen LM, Verdouw PD,
Schalekamp MADH (1998) Angiotensin production by the heart:
a quantitative study in pigs with the use of radiolabeled
angiotensin infusions. Circulation 98:73–81
van Kats JP, Duncker DJ, Haitsma DB, Schuijt MP, Niebuur R,
Stubenitsky R, Boomsma F, Schalekamp MADH, Verdouw PD,
Danser AHJ (2000) Angiotensin-converting enzyme inhibition
and angiotensin II type 1 receptor blockade prevent cardiac
remodeling in pigs after myocardial infarction: role of tissue
angiotensin II. Circulation 102:1556–1563
Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL (2002)
Spironolactone improves angiotensin-induced vascular changes
and oxidative stress. Hypertension 40:504–510
Wehling M (2005) Effects of aldosterone and mineralocorticoid
receptor blockade on intracellular electrolytes. Heart Fail Rev
10:39–46
Wehling M, Neylon CB, Fullerton M, Bobik A, Funder JW (1995)
Nongenomic effects of aldosterone on intracellular Ca2+ in
vascular smooth muscle cells. Circ Res 76:973–979
White PC, Rainey WE (2005) Editorial: polymorphisms in CYP11B
genes and 11-hydroxylase activity. J Clin Endocrinol Metab
90:1252–1255
Xiao F, Puddefoot JR, Barker S, Vinson GP (2004) Mechanism for
aldosterone potentiation of angiotensin II-stimulated rat arterial
smooth muscle cell proliferation. Hypertension 44:340–345
Yee KM, Pringle SD, Struthers AD (2001) Circadian variation in the
effects of aldosterone blockade on heart rate variability and QT
dispersion in congestive heart failure. J Am Coll Cardiol
37:1800–1807
Young MJ, Clyne CD, Cole TJ, Funder JW (2001) Cardiac
steroidogenesis in the normal and failing heart. J Clin Endocrinol
Metab 86:5121–5126
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (2000)
Effects of an angiotensin-converting-enzyme inhibitor, ramipril,
on cardiovascular events in high-risk patients. The Heart Out-
comes Prevention Evaluation Study Investigators. N Engl J Med
342:145–153
162 Naunyn-Schmiedeberg’s Arch Pharmacol (2006) 374:153–162